


**Remarks**

The present communication is a Preliminary Amendment which accompanies a Request for a Continuation Application, filed pursuant to 37 CFR 1.53(b). Of the originally filed claims 1-40, Applicants have cancelled claims 6, 7, 20-22, and 30-40, without prejudice and amended claims 1-5, 11-13, 23, and 24. Applicants include as a separate document, a copy of the amended claims marked-up to show the changes from previously pending claims. Applicants respectfully submit that the amended claims are fully supported by the specification, as filed.

Applicants also have added new claims 41 and 42. Applicants submit that new Claims 41 and 42 also find support in the specification as well as in original Claims 6 and 7 and therefore, add no new matter. Accordingly, Applicants respectfully request entry of amended claims 1-5, 11-13, 23, and 24 and new claims 41 and 42 into the record.

Respectfully submitted,  
Jean-Marc Roch, *et al.*



Dianne Casuto  
Registration No. 40,943  
Attorney for Applicants

ABBOTT LABORATORIES  
D-377/AP6D-2  
100 Abbott Park Road  
Abbott Park, IL 60064-6050  
Telephone: (847) 938-3137  
Facsimile: (847) 938-2623

090413040" 82742860

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Jean-Marc Roch, *et al.*

Serial No.:

Filed: April 2, 2001

For: HUMAN ENDOSULFINE GENE

Case No.: 6024.US.C1

Date: April 2, 2001

EXPRESS MAIL NO.: EL 507386273 US

**Certificate of Mailing under 37 CFR §1.10:**

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service as Express Mail Post Office to Addressee Service with sufficient postage in an envelope addressed to:

Assistant Commissioner for Patents  
Box Patent Application  
Washington, D.C. 20231

on 4-2-01

Name of person signing  
this certificate: Linda L. Powell

Signature Linda Powell

**ATTACHMENT TO PRELIMINARY AMENDMENT OF APRIL 2, 2001**  
**(Version with Markings to Show Changes to Previously Pending Claims)**

Assistant Commissioner for Patents

Washington, D.C. 20231

1. (amended) ~~An isolated or purified polynucleotide~~ **[comprising a nucleotide sequence]**  
which encodes a human endosulfine and **[fragments and compliments]**complements  
thereof.

2. (amended) The polynucleotide of Claim 1 wherein said **[nucleotide]**polynucleotide is  
SEQ ID NO:1.

3. (amended) The polynucleotide of Claim 1 wherein said **[nucleotide]**polynucleotide is  
SEQ ID NO:2.

F02010" S2T42350

4. (amended) The polynucleotide of Claim 1 wherein said **[nucleotide]polynucleotide** is SEQ ID NO:1 from about nucleotide position 107 to about nucleotide position 460.

5. (amended) The polynucleotide of Claim 1 wherein said **[nucleotide]polynucleotide** is SEQ ID NO:1 from about nucleotide position 107 to about nucleotide position 472.

11. (amended) The recombinant expression vector of Claim 8 wherein the vector portion of said expression vector is selected from the group consisting of pProEx1 and pcDNA3.1.

12. (amended) The recombinant expression vector of Claim 9 wherein the vector portion of said expression vector is selected from the group consisting of pProEx1 and pcDNA3.1.

13. (amended) The recombinant expression vector of Claim 10 wherein the vector portion of said expression vector is selected from the group consisting of pProEx1 and pcDNA3.1.

23. (amended) A method for producing a polypeptide containing at least one human endosulfine epitope comprising incubating host cells transformed with an expression vector wherein said expression vector comprises a nucleotide sequence which encodes a human endosulfine, and producing said polypeptide.

24. (amended) The method of Claim 23 wherein said nucleotide sequence which encodes a human endosulfine has the sequence SEQ ID NO:2 **and [fragments and compliments]complements** thereof.